Angiogenesis in Melanoma

Seminars in Oncology

Volumn 34, Issue 6, 2007, Pages 555-565

  Mahabeleshwar, Ganapati H ^a   Byzova, Tatiana V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATN 161; BATIMASTAT; BEVACIZUMAB; CILENGITIDE; DACARBAZINE; E 7820; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTEGRIN; INTERLEUKIN 8; MARIMASTAT; METALLOPROTEINASE; MONOCLONAL ANTIBODY CNTO 95; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY LM 609; PLACENTAL GROWTH FACTOR; PRINOMASTAT; PROTEIN INHIBITOR; SEMAXANIB; SORAFENIB; SULFONAMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VOLOCIXIMAB;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; INHIBITION KINETICS; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOLID TUMOR; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HUMANS; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASES; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36849078591     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.09.009     Document Type: Article

References (86)

1. Folkman J. Angiogenesis. Annu Rev Med 57 (2006) 1-18
2. Warren B.A., and Shubik P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 15 (1966) 464-478
3. Hubler Jr. W.R., and Wolf Jr. J.E. Melanoma. Tumor angiogenesis and human neoplasia. Cancer 38 (1976) 187-192
4. Elder D.E., Van Belle P., Elenitasas R., et al. Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg 15 (1996) 336-348
5. Meier F., Satyamoorthy K., Nesbit M., et al. Molecular events in melanoma development and progression. Front Biosci 3 (1998) D1005-D1010
6. Tuthill R.J., and Reed R.I. Failure of senescence in the dysplasia-melanoma sequence: Demonstration using a tissue microarray and a revised paradigm for melanoma. Semin Oncol (2007)
7. Jhappan C., Noonan F.P., and Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 22 (2003) 3099-3112
8. Lin J.Y., and Fisher D.E. Melanocyte biology and skin pigmentation. Nature 445 (2007) 843-850
9. Bordeaux J.S., Lu K.Q., and Cooper K.D. Melanoma: Prevention and early detection. Semin Oncol (2007)
10. Michaylira C.Z., and Nakagawa H. Hypoxic miroenvirornment as a cradle for melanoma development and progression. Cancer Biol Ther 5 (2006) 476-479
11. Hendrix M.J., Seftor E.A., Seftor R.E., et al. Reprogramming metastatic tumor cells with embryonic microenvironments. Nat Rev Cancer 7 (2007) 246-255
12. Wanebo H.J., Argiris A., Bergsland E., et al. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev 25 (2006) 279-292
13. Gille J. Antiangiogenic cancer therapies get their act together: Current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 15 (2006) 175-186
14. Sparano J.A., Gray R., Giantonio B., et al. Evaluating antiangiogenesis agents in the clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res 10 (2004) 1206-1211
15. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 62 (2005) 1021-1032
16. Vacca A., Ria R., Ribatti D., et al. [Angiogenesis and tumor progression in melanoma]. Recenti Prog Med 91 (2000) 581-587
17. Plum S.M., Holaday J.W., Ruiz A., et al. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19 (2000) 1294-1303
18. Sessa C., Vigano L., Grasselli G., et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 42 (2006) 171-178
19. Odorisio T., Cianfarani F., Failla C.M., et al. The placenta growth factor in skin angiogenesis. J Dermatol Sci 41 (2006) 11-19
20. Donnini S., Machein M.R., Plate K.H., et al. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol 189 (1999) 66-71
21. Luttun A., Autiero M., Tjwa M., et al. Genetic dissection of tumor angiogenesis: Are PlGF and VEGFR-1 novel anti-cancer targets?. Biochim Biophys Acta 1654 (2004) 79-94
22. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67 (1999) 12-18
23. Liu G., Zhang F., Lee J., et al. Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1. Cytokine 31 (2005) 241-249
24. Mahler D.A., Huang S., Tabrizi M., et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: A pilot study. Chest 126 (2004) 926-934
25. Melnikova V.O., and Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 19 (2006) 395-405
26. Mueller B.M. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 213 (1996) 65-80
27. Delbaldo C., Masouye I., Saurat J.H., et al. Plasminogen activation in melanocytic neoplasia. Cancer Res 54 (1994) 4547-4552
28. Hearing V.J., Law L.W., Corti A., et al. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48 (1988) 1270-1278
29. Min H.Y., Doyle L.V., Vitt C.R., et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56 (1996) 2428-2433
30. Berkenblit A., Matulonis U.A., Kroener J.F., et al. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. Gynecol Oncol 99 (2005) 50-57
31. Muehlenweg B., Sperl S., Magdolen V., et al. Interference with the urokinase plasminogen activator system: A promising therapy concept for solid tumours. Expert Opin Biol Ther 1 (2001) 683-691
32. Kuphal S., Bauer R., and Bosserhoff A.K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 24 (2005) 195-222
33. Hynes R.O. The emergence of integrins: A personal and historical perspective. Matrix Biol 23 (2004) 333-340
34. Eskens F.A., Dumez H., Hoekstra R., et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39 (2003) 917-926
35. Stupack D.G., and Cheresh D.A. Integrins and angiogenesis. Curr Top Dev Biol 64 (2004) 207-238
36. Seftor R.E. Role of the beta3 integrin subunit in human primary melanoma progression: Multifunctional activities associated with alpha(v)beta3 integrin expression. Am J Pathol 153 (1998) 1347-1351
37. Posey J.A., Khazaeli M.B., DelGrosso A., et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16 (2001) 125-132
38. Nikolopoulos S.N., Blaikie P., Yoshioka T., et al. Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 6 (2004) 471-483
39. Ziober B.L., Chen Y.Q., Ramos D.M., et al. Expression of the alpha7beta1 laminin receptor suppresses melanoma growth and metastatic potential. Cell Growth Differ 10 (1999) 479-490
40. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5 (2004) 816-826
41. Ramakrishnan V., Bhaskar V., Law D.A., et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5 (2006) 273-286
42. Brown L.F., Papadopoulos-Sergiou A., Berse B., et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 145 (1994) 610-623
43. Geissinger E., Weisser C., Fischer P., et al. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 62 (2002) 4820-4828
44. Reiniger I.W., Wolf A., Welge-Lussen U., et al. Osteopontin as a serologic marker for metastatic uveal melanoma: Results of a pilot study. Am J Ophthalmol 143 (2007) 705-707
45. Semba T., Funahashi Y., Ono N., et al. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: Possible value of integrin alpha2 on platelets as a biological marker. Clin Cancer Res 10 (2004) 1430-1438
46. Pochec E., Litynska A., Amoresano A., et al. Glycosylation profile of integrin alpha 3 beta 1 changes with melanoma progression. Biochim Biophys Acta 1643 (2003) 113-123
47. Miller D.H., Khan O.A., Sheremata W.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 (2003) 15-23
48. Felding-Habermann B., Fransvea E., O'Toole T.E., et al. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 19 (2002) 427-436
49. Seftor R.E., Seftor E.A., Stetler-Stevenson W.G., et al. The 72 kDa type IV collagenase is modulated via differential expression of alpha v beta 3 and alpha 5 beta 1 integrins during human melanoma cell invasion. Cancer Res 53 (1993) 3411-3415
50. Tucker G.C. Integrins: Molecular targets in cancer therapy. Curr Oncol Rep 8 (2006) 96-103
51. Cianfrocca M.E., Kimmel K.A., Gallo J., et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 94 (2006) 1621-1626
52. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2 (2002) 657-672
53. Chirco R., Liu X.W., Jung K.K., et al. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25 (2006) 99-113
54. Nagase H., Visse R., and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69 (2006) 562-573
55. Chen W.T., and Wang J.Y. Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann N Y Acad Sci 878 (1999) 361-371
56. Hofmann U.B., Westphal J.R., Van Muijen G.N., et al. Matrix metalloproteinases in human melanoma. J Invest Dermatol 115 (2000) 337-344
57. Kerkela E., and Saarialho-Kere U. Matrix metalloproteinases in tumor progression: Focus on basal and squamous cell skin cancer. Exp Dermatol 12 (2003) 109-125
58. Nikkola J., Vihinen P., Vuoristo M.S., et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11 (2005) 5158-5166
59. Durko M., Navab R., Shibata H.R., et al. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta 1356 (1997) 271-280
60. Cotignola J., Reva B., Mitra N., et al. Matrix metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC Med Genet 8 (2007) 10
61. Schnaeker E.M., Ossig R., Ludwig T., et al. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: Prerequisite in human melanoma cell invasion. Cancer Res 64 (2004) 8924-8931
62. Wojtowicz-Praga S., Torri J., Johnson M., et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 16 (1998) 2150-2156
63. Rudek M.A., Figg W.D., Dyer V., et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 19 (2001) 584-592
64. Jin X., Yagi M., Akiyama N., et al. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 97 (2006) 1327-1334
65. Wojtowicz-Praga S., Low J., Marshall J., et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14 (1996) 193-202
66. Bodey B., Bodey Jr. B., Groger A.M., et al. Invasion and metastasis: The expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 15 (2001) 175-180
67. Airola K., Karonen T., Vaalamo M., et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80 (1999) 733-743
68. Hofmann U.B., Westphal J.R., Zendman A.J., et al. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 191 (2000) 245-256
69. Anand-Apte B., Bao L., Smith R., et al. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol 74 (1996) 853-862
70. Bloomston M., Shafii A., Zervos E., et al. TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo. Am J Surg 189 (2005) 675-679
71. Pavlaki M., and Zucker S. Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22 (2003) 177-203
72. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295 (2002) 2387-2392
73. Folkman J. Tumor angiogensis: Role in regulation of tumor growth. Symp Soc Dev Biol 30 (1974) 43-52
74. Jain R.K., Duda D.G., Clark J.W., et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40
75. Shih T., and Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 (2006) 1779-1802
76. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 95 (2006) 581-586
77. Rudge J.S., Thurston G., Davis S., et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol 70 (2005) 411-418
78. Mita M.M., Rowinsky E.K., Forero L., et al. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol 59 (2007) 165-174
79. Rasmussen H.S., and McCann P.P. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol Ther 75 (1997) 69-75
80. Quirt I., Bodurth A., Lohmann R., et al. Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 20 (2002) 431-437
81. Lee L., Sharma S., Morgan B., et al. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 57 (2006) 761-771
82. Basche M., Gustafson D.L., Holden S.N., et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12 (2006) 5471-5480
83. Miller D.W., Vosseler S., Mirancea N., et al. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol 167 (2005) 1389-1403
84. Trikha M., Zhou Z., Nemeth J.A., et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110 (2004) 326-335
85. Gogas H., Polyzos A., Stavrinidis I., et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 17 (2006) 1835-1841
86. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147